» Articles » PMID: 38466368

Global Dilemma and Needs Assessment Toward Achieving Sustainable Development Goals in Controlling Leishmaniasis

Abstract

Leishmaniasis is a disease of poverty that imposes a devastating medical, social, and economic burden on over 1 billion people nationwide. To date, no in-depth study to analyze the major global challenges and needs assessment has been carried out. This investigation aimed to explore a comprehensive narrative review of leishmaniasis's main challenges and initially highlight obstacles that might impede the implementation of control measures. Also, we propose a specific list of priorities for needs assessment. The presence of socioeconomic factors, multiple clinical and epidemiological forms, various Leishmania species, the complexity of the life cycle, the absence of effective drugs and vaccines, and the lack of efficient vector and reservoir control make this organism unique and sophisticated in playing a tangled role to react tricky with its surrounding environments, despite extensive efforts and implementation of all-inclusive former control measures. These facts indicate that the previous strategic plans, financial support, and basic infrastructures connected to leishmaniasis surveillance are still insufficient. Strengthening the leishmaniasis framework in a context of accelerated programmatic action and intensification of cross-cutting activities along with other neglected tropical diseases (NTDs) is confidently expected to result in greater effectiveness, cost-benefit, and fruitful management. Sensitive diagnostics, effective therapeutics, and efficacious vaccines are vital to accelerating advancement toward elimination, and reducing morbidity/mortality and program costs. Collective actions devoted by all sectors and policy-makers can hopefully overcome technical and operational barriers to guarantee that effective and coordinated implementation plans are sustained to meet the road map for NTDs 2021- 2030 goals.

Citing Articles

Putrescine Depletion in Parasites Causes Immediate Proliferation Arrest Followed by an Apoptosis-like Cell Death.

Johnston J, Taylor J, Nahata S, Gatica-Gomez A, Anderson Y, Kiger S Pathogens. 2025; 14(2).

PMID: 40005515 PMC: 11858418. DOI: 10.3390/pathogens14020137.


Evaluation of the Anti-Leishmanial Activity of the Hydroalcoholic Extract of Green Algae (Spirogyra): Investigation of Weight Indicators (Lesion Size and Organ Weights) in BALB/c Mice.

Zarezadeh Mehrizi R, Bafghi A, Nasiri V, Sarafraz Ardakani M, Meybodi M, Zare-Zardini H Acta Parasitol. 2025; 70(1):51.

PMID: 39918617 DOI: 10.1007/s11686-025-00994-4.


Natural Product Identification and Molecular Docking Studies of Leishmania Major Pteridine Reductase Inhibitors.

Arthur M, Hanson G, Broni E, Sakyi P, Mensah-Brown H, Miller 3rd W Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861069 PMC: 11768234. DOI: 10.3390/ph18010006.


Prevalence of human visceral leishmaniasis and its risk factors in Eastern Africa: a systematic review and meta-analysis.

Geto A, Berihun G, Berhanu L, Desye B, Daba C Front Public Health. 2024; 12():1488741.

PMID: 39659723 PMC: 11628699. DOI: 10.3389/fpubh.2024.1488741.


Compared Antileishmanial Activity of Clomiphene and Tamoxifen.

Sifontes-Rodriguez S, Escalona-Montano A, Mondragon Flores R, Mollineda-Diogo N, Monzote Fidalgo L, Mondragon-Castelan M Biomedicines. 2024; 12(10).

PMID: 39457604 PMC: 11504008. DOI: 10.3390/biomedicines12102290.

References
1.
Bailey F, Mondragon-Shem K, Hotez P, Ruiz-Postigo J, Al-Salem W, Acosta-Serrano A . A new perspective on cutaneous leishmaniasis-Implications for global prevalence and burden of disease estimates. PLoS Negl Trop Dis. 2017; 11(8):e0005739. PMC: 5552022. DOI: 10.1371/journal.pntd.0005739. View

2.
Bamorovat M, Sharifi I, Agha Kuchak Afshari S, Karamoozian A, Tahmouresi A, Heshmatkhah A . Poor adherence is a major barrier to the proper treatment of cutaneous leishmaniasis: A case-control field assessment in Iran. Int J Parasitol Drugs Drug Resist. 2022; 21:21-27. PMC: 9791244. DOI: 10.1016/j.ijpddr.2022.11.006. View

3.
Alvar J, Velez I, Bern C, Herrero M, Desjeux P, Cano J . Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012; 7(5):e35671. PMC: 3365071. DOI: 10.1371/journal.pone.0035671. View

4.
Bamorovat M, Sharifi I, Dabiri S, Meymandi S, Karamoozian A, Amiri R . Major risk factors and histopathological profile of treatment failure, relapse and chronic patients with anthroponotic cutaneous leishmaniasis: A prospective case-control study on treatment outcome and their medical importance. PLoS Negl Trop Dis. 2021; 15(1):e0009089. PMC: 7872302. DOI: 10.1371/journal.pntd.0009089. View

5.
Kumari P, Mamud A, Jha A . Review on the Drug Intolerance and Vaccine Development for the Leishmaniasis. Curr Drug Targets. 2023; 24(13):1023-1031. DOI: 10.2174/0113894501254585230927100440. View